The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer.: a NCDB analysis

BMC Cancer

Table 3 Subgroup analysis in multivariate Cox regression model for difference of overall survival in three cohorts

Subgroups	Strategy	Adjusted HR	95% CI of HR	Adjusted P value
Reference	NT	1.000	1.000	1.000
Age
≤55	AT	1.074	0.712-1.619	0.735
≤55	CT	1.077	0.734-1.581	0.704
56-65	AT	0.861	0.615-1.206	0.384
56-65	CT	1.182	0.859-1.626	0.305
66-75	AT	1.039	0.740-1.459	0.825
66-75	CT	0.771	0.476-1.250	0.292
>75	AT	2.399	1.304-4.413	0.005
>75	CT	3.723	0.966-14.344	0.056
Sex
Male	AT	1.102	0.899-1.351	0.351
Male	CT	1.183	0.947-1.477	0.139
Female	AT	1.104	0.659-1.848	0.707
Female	CT	0.636	0.317-1.277	0.203
Year of diagnosis
2006-2010	AT	1.053	0.839-1.321	0.657
2006-2010	CT	1.027	0.775-1.360	0.855
2011-2015	AT	1.136	0.806-1.602	0.465
2011-2015	CT	1.237	0.898-1.704	0.194
Charleson score
0	AT	1.124	0.888-1.422	0.332
0	CT	1.076	0.841-1.377	0.560
1	AT	0.902	0.623-1.306	0.586
1	CT	1.305	0.835-2.039	0.242
≥2	AT	2.517	1.062-5.965	0.036
≥2	CT	0.736	0.166-3.266	0.687
Facility type
Community	AT	0.385	0.057-2.608	0.328
Community	CT	713.823	12.241-41626.965	0.002
Comprehensive Community	AT	1.078	0.759-1.531	0.675
Comprehensive Community	CT	1.140	0.805-1.615	0.460
Academic/Research	AT	1.079	0.842-1.383	0.547
Academic/Research	CT	1.256	0.943-1.674	0.120
Integrated Network	AT	1.127	0.529-2.401	0.757
Integrated Network	CT	0.787	0.302-2.047	0.623
Histology type
ESCC	AT	1.542	0.988-2.407	0.057
ESCC	CT	0.805	0.453-1.431	0.459
EAC	AT	1.022	0.839-1.243	0.831
EAC	CT	1.155	0.928-1.437	0.196
c Stage
T1N+	AT	0.691	0.321-1.486	0.344
T1N+	CT	1.323	0.760-2.304	0.322
T2	AT	1.074	0.886-1.301	0.468
T2	CT	1.078	0.856-1.359	0.524
T2N0	AT	1.094	0.856-1.398	0.473
T2N0	CT	1.259	0.882-1.797	0.205
T2N+	AT	1.203	0.860-1.683	0.280
T2N+	CT	0.999	0.734-1.360	0.997
T1+T2	AT	1.018	0.846-1.225	0.849
T1+T2	CT	1.122	0.909-1.385	0.283

Covariates in Cox model were all categorical variables, included age, sex, race, type of insurance, income, education, rurality, patient comorbidity, year of diagnosis, type of facility, histology type, tumor location and clinical T and N stage.
Adjusted P value and Hazard Ratio (HR) were derived from the model, putting NT group as reference

ISSN: 1471-2407